TY - JOUR
T1 - Intergroup Hodgkin's disease in children study of stages I and II
T2 - A preliminary report
AU - Sullivan, M. P.
AU - Fuller, L. M.
AU - Chen, T.
AU - Fisher, R.
AU - Fryer, C.
AU - Gehan, E.
AU - Gilchrist, G. S.
AU - Hays, D.
AU - Hanson, W.
AU - Heller, R.
AU - Higgins, G.
AU - Jenkin, D.
AU - Kung, F.
AU - Sheehan, W.
AU - Tefft, M.
AU - Ternberg, J.
AU - Wharam, M.
PY - 1982
Y1 - 1982
N2 - The intergroup study of involved-field (IF) radiotherapy, IF radiotherapy plus MOPP chemotherapy, and extended-field (EF) radiotherapy for treatment of Hodgkin's disease in children has assessed 305 patients. Of these, 279 were 'not ineligible' (no immediate cause for disqualification). Among 223 randomized patients, 144 were evaluable, 131 had documentation of complete or partial remission, 20 of the remitters relapsed, and two died. Among 62 nonrandomized patients with favorable presentations (unilateral upper neck, unilateral inguinal, or massive mediastinal disease), 29 had documented remission, two relapsed, and none died. Length of initial disease control (LIDC) was used to measure duration of response. LIDC was best in patients given IF plus MOPP, and 95% are disease free. EF was better than IF radiotherapy (P = 0.004). Of the disease characteristics prognostic for response (stage, histologic subtype, and presence of symptoms), only the last factor had a statistically significant effect on LIDC (P = 0.004). Ninety-six percent of the patients survive. Using criteria developed by the committee, 23% of the staging procedures reviewed were nonevaluable and 28% of the radiotherapy treatments were nonevaluable. The necessity for criteria for evaluation of staging and treatment is certain. Length of followup is too short for correlations of treatment with significant late effects and for relevant therapeutic recommendations.
AB - The intergroup study of involved-field (IF) radiotherapy, IF radiotherapy plus MOPP chemotherapy, and extended-field (EF) radiotherapy for treatment of Hodgkin's disease in children has assessed 305 patients. Of these, 279 were 'not ineligible' (no immediate cause for disqualification). Among 223 randomized patients, 144 were evaluable, 131 had documentation of complete or partial remission, 20 of the remitters relapsed, and two died. Among 62 nonrandomized patients with favorable presentations (unilateral upper neck, unilateral inguinal, or massive mediastinal disease), 29 had documented remission, two relapsed, and none died. Length of initial disease control (LIDC) was used to measure duration of response. LIDC was best in patients given IF plus MOPP, and 95% are disease free. EF was better than IF radiotherapy (P = 0.004). Of the disease characteristics prognostic for response (stage, histologic subtype, and presence of symptoms), only the last factor had a statistically significant effect on LIDC (P = 0.004). Ninety-six percent of the patients survive. Using criteria developed by the committee, 23% of the staging procedures reviewed were nonevaluable and 28% of the radiotherapy treatments were nonevaluable. The necessity for criteria for evaluation of staging and treatment is certain. Length of followup is too short for correlations of treatment with significant late effects and for relevant therapeutic recommendations.
UR - http://www.scopus.com/inward/record.url?scp=0020079418&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020079418&partnerID=8YFLogxK
M3 - Article
C2 - 7042092
AN - SCOPUS:0020079418
SN - 0361-5960
VL - 66
SP - 937
EP - 947
JO - Cancer treatment reports
JF - Cancer treatment reports
IS - 4
ER -